Skip to content

Study on the mechanism and safety evaluation of hyperhemopoiesis in human

Study on the mechanism and safety evaluation of hyperhemopoiesis in human

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031902
Enrollment
Unknown
Registered
2020-04-14
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

AAA group:red blood cell apheresis
WB group:whole blood collection
AAA group2:red blood cell apheresis
BT group:red blood cell apheresis and transfusion

Sponsors

The Fourth Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: On the basis of blood donation health consultation, healthy volunteers aged 18-40 were selected, male, weight over than 70kg, the pressure blood was 120-140/60-90 mmHg, Pulse pressure difference was over than 30mmHg, the pulse was 60-100bpm. Hemoglobin > 120g/L, platelet > 110 x 10^9/L; the result of blood biochemistry and other examination result were normal.

Exclusion criteria

Exclusion criteria: Abnormal or inhibited hematopoietic function of bone marrow; cardiopulmonary insufficiency; fever or infectious diseases; taking drugs to inhibit compensatory cardiovascular response, such as ß - blockers; taking drugs to promote or inhibit hematopoietic function; blood donation history within half a year (related questionnaire in health consultation).

Design outcomes

Primary

MeasureTime frame
RBC;Hb;Hct;RET%;RET;IS;SF;

Countries

China

Contacts

Public ContactOuyang Xilin

The Fourth Medical Center of Chinese PLA General Hospital

ouy70304@163.com+86 13381361899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026